News from viiv healthcare A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 02, 2015, 03:00 ET

ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries

Agreement reinforces ViiV Healthcare commitment to improving access to HIV treatments   ViiV Healthcare and Desano Pharmaceuticals...

May 26, 2015, 09:00 ET

ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an...

May 06, 2015, 04:51 ET

ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine   ViiV Healthcare today announced the start of a...

Feb 04, 2015, 09:30 ET

ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

 ViiV Healthcare today announced the launch of a four-year, $10 million initial investment to fuel a concerted community response to the HIV...

Dec 04, 2014, 11:29 ET

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug...

Oct 20, 2014, 09:00 ET

ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

 ViiV Healthcare today announced seven Positive Action Southern Initiative grant awardees in Georgia, Louisiana and Mississippi for...

Aug 25, 2014, 19:32 ET

ViiV Healthcare recibe aprobación de la FDA para Triumeq® (abacavir, dolutegravir y lamivudine), una nueva régimen de tableta única para el tratamiento de la infección por VIH-1

El material multimedia relacionado con el aviso a continuación ya está disponible. El material incluye: material complementario en video,...

Aug 25, 2014, 09:00 ET

Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

 On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq® (abacavir 600mg, dolutegravir...

Aug 22, 2014, 15:46 ET

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and...

Jun 14, 2014, 13:59 ET

ViiV Healthcare annonce un nouveau projet de collaboration avec Janssen en vue de mettre au point un comprimé unique destiné au traitement d'entretien des patients contaminés par le VIH-1

- Cet accord représente le premier projet de collaboration externe de ViiV Healthcare dans le cadre de la mise au point d'un comprimé...

Jun 14, 2014, 13:53 ET

ViiV Healthcare meldet neue Kooperation mit Janssen zwecks Untersuchung eines Einzeltablettenpräparats für die Erhaltungstherapie bei HIV-1

- Vereinbarung ist ViiV Healthcares erste externe Kooperation zur Entwicklung einer Einzeltablette mit zwei kombinierten Wirkstoffen: Dolutegravir...

Jun 13, 2014, 18:06 ET

ViiV Healthcare y Janssen investigarán el régimen de tableta única para el tratamiento de mantenimiento del VIH-1

- El acuerdo es la primera colaboración externa de ViiV Healthcare para el desarrollo de una tableta de dos fármacos combinados:...

Jun 12, 2014, 06:17 ET

ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and...

Jun 10, 2014, 07:00 ET

Una encuesta nacional identifica posibles obstáculos para el tratamiento contra el VIH en los EE. UU.

 ViiV Healthcare anunció hoy nuevos datos de una encuesta que proporciona importantes detalles que pueden ayudar a explicar el motivo por...

Jun 10, 2014, 07:00 ET
National Survey Identifies Potential Barriers to HIV Treatment Use in U.S. (PRNewsFoto/ViiV Healthcare)

National Survey Identifies Potential Barriers to HIV Treatment Use in U.S.

 ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in...

Apr 01, 2014, 14:30 ET

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name...

Mar 19, 2014, 09:45 ET

ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence

 ViiV Healthcare today issued a new request for letters of interest (LOIs) for the sixth round of its Positive Action Southern Initiative...

Jan 21, 2014, 06:52 ET

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

 ViiV Healthcare today announced that the European Commission has approved Tivicay™ (dolutegravir), an integrase inhibitor, for use...

Nov 22, 2013, 09:00 ET

Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

 ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

Oct 22, 2013, 12:53 ET

ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV

ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR)...